my personal edition > allergy other > news


  E-Mail this DGDispatch to a colleague

DGDispatch

Once-Daily Intranasal Rofleponide 200 mcg Spray Rated More Effective Than Mometasone in Seasonal Allergic Rhinitis: Presented at AAAAI

By Bonnie Darves

SAN FRANCISCO, CA -- March 24, 2004 -- The new intranasal glucocorticosteroid spray, rofleponide palmitate 200 mcg once daily for 2 weeks appears to provide better symptomatic control than the same dose of mometasone furoate, according to results of a study presented here at the American Academy of Allergy, Asthma & Immunology 60^th Annual Meeting.

Lead investigator Dean Atkinson, MD, Oklahoma Allergy & Asthma Clinic, Oklahoma City, Oklahoma, United States, and colleagues reported results of a multicentre, randomised, double-blind study that compared the two long-acting glucocorticosteroids and placebo in 660 adults and adolescents. Patients' average age was 38 years, and 67% of them were females. All were allergic to mountain cedar pollen.

The study was initiated after mountain cedar pollen counts had been elevated for at least 7 days. Patients were required to have moderate to severe rhinitis symptoms for the past 3½ days. Total nasal symptom scores (TNSS) at baseline were a mean of 8.5 to 9.3. They were treated once daily for 2 weeks with 1 of 3 doses of rofleponide (20 mcg, 100 mcg, 200 mcg), mometasone 200 mcg or placebo.

The 20-mcg rofleponide spray provided significant relief of rhinitis symptoms according to both the morning and evening TNSS versus placebo, with the 200 mcg dose achieving an even better response (20 mcg, P < .05 for both; 200 mcg, P < .001 for both). All 3 rofleponide doses significantly improved the patients' morning total instantaneous symptom score (TISS) compared with placebo (20 mcg, P = .007; 100 mcg, P = .025; 200 mcg, P < .001), Dr. Atkinson said.

The extent of improvement in TNSS and TISS documented with the 200-mcg dose of rofleponide exceeded that seen with mometasone. The rofleponide intranasal spray reduced the TNSS by more than 3 points, whereas the mometasone spray decreased the TNSS by less than 3 points. The 20- and 100-mcg doses of rofleponide also showed improvements in TNSS and TISS, with results numerically similar to those seen in the mometasone group.

Thus, the authors concluded, rofleponide shows promise for relieving symptoms of seasonal allergic rhinitis, with the 200 mcg once-daily dose being more effective than the same dose of mometasone.

The study was supported by AstraZeneca.


[Study Title: A Comparison of Rofleponide Palmitate Nasal Spray (RPNS) With Placebo and Mometasone Furoate Nasal Spray (MFNS) in Adolescent and Adult Patients With Seasonal (Mountain Cedar) Allergic Rhinitis. Poster 599]

E-Mail this DGDispatch to a colleague

To print, use this version